Tumor immunotherapy: A crucial area for immediate focus

Ziyuan Zhang; Jingtian Qi; Xianbin Kong

doi:10.36922/EJMO025120059

Eurasian Journal of Medicine and Oncology ›› 2025, Vol. 9 ›› Issue (2) : 1 -2. DOI: 10.36922/EJMO025120059

EDITORIAL

research-article

Tumor immunotherapy: A crucial area for immediate focus

Author information +

History +

PDF (407KB)

Cite this article

Download citation ▾

Ziyuan Zhang, Jingtian Qi, Xianbin Kong. Tumor immunotherapy: A crucial area for immediate focus. Eurasian Journal of Medicine and Oncology, 2025, 9(2): 1-2 DOI:10.36922/EJMO025120059

登录浏览全文

4963

注册一个新账户忘记密码

Conflict of interest

Xianbin Kong is an Editorial Board Member of this journal but was not in any way involved in the editorial and peer-review process conducted for this paper, directly or indirectly. Separately, other authors declared that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Yildiz B, Acar R. Immunotherapy in geriatric patients with advanced cancer. EJMO. 2020; 4(3):209-214. doi: 10.14744/ejmo.2020.44446

[2]	Esfahani K, Meti N, Miller WH Jr., Hudson M. Adverse events associated with immune checkpoint inhibitor treatment for cancer. CMAJ. 2019; 191(2):E40-E46. doi: 10.1503/cmaj.180870

[3]	Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017; 168(4):707-723. doi: 10.1016/j.cell.2017.01.017

[4]	Wang Y, Deng W, Li N, et al. Combining immunotherapy and radiotherapy for cancer treatment: Current challenges and future directions. Front Pharmacol. 2018; 9:185. doi: 10.3389/fphar.2018.00185

[5]	Wang M, Yu F, Zhang Y. Present and future of cancer nano-immunotherapy: Opportunities, obstacles and challenges. Mol Cancer. 2025; 24(1):26. doi: 10.1186/s12943-024-02214-5